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obese-NL to the obese-NAFLD groups, whereas total hepatic insulin extraction (molar amount removed) was greater in
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extrahepatic insulin extraction progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups.
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Introduction
Obesity is associated with nonalcoholic fatty liver disease (NAFLD), 
multiorgan insulin resistance, and hyperinsulinemia, which are 
major risk factors for both type 2 diabetes and coronary heart disease 
(1–4). Although hyperinsulinemia and insulin resistance are likely 
involved in the pathogenesis of NAFLD (5), excess intrahepatic tri-
glyceride (IHTG) content could also contribute to hyperinsulinemia 
and insulin resistance. The liver is important in regulating systemic 
plasma insulin concentrations, because it is the major site for insulin 
clearance; in individuals who are lean and healthy, a large portion 
(~50%) of the insulin delivered to the liver is cleared during first-
pass transit, and an additional 20% is cleared through subsequent 
passes (6, 7). The remaining 30% of insulin secreted by the pancreas 
is removed by extrahepatic organs, primarily the kidneys and skel-
etal muscle (6, 8). Increased insulin secretion and impaired hepat-
ic insulin clearance in individuals with NAFLD could contribute to 
insulin resistance by chronic exposure of insulin-sensitive tissues to 
large amounts of insulin, which can downregulate insulin receptor 
binding affinity and insulin receptor numbers (9–12). Even 24 hours 
of an experimentally induced increase in plasma insulin concentra-
tion causes hepatic and skeletal muscle insulin resistance (13), and a 
single dose of a pharmacological agent that decreases insulin secre-
tion lowers 24-hour plasma glucose and insulin concentrations and 
improves oral glucose tolerance (14) in healthy, lean adults. Howev-
er, the relationship between IHTG content and insulin kinetics is not 
clear because of conflicting data from different studies that found 
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plasma glucose concentrations, plasma 
glucose 2 hours after glucose ingestion, 
and hemoglobin A1c (HbA1c) were 
higher in the obese-NAFLD group 
than in the obese-NL and lean-NL 
groups, with no differences between 
the obese-NL and lean-NL groups 
(Table 1). Fasting plasma insulin and 
C-peptide concentrations increased 
progressively from the lean-NL to the 
obese-NL to the obese-NAFLD groups 
(Table 1). Both hepatic insulin sensi-
tivity (assessed as the reciprocal of the 
product of basal endogenous glucose 
production rate and basal plasma insu-
lin concentration) and muscle insulin 
sensitivity (assessed as the glucose dis-
posal rate relative to the plasma insu-
lin concentration during the HECP) 
decreased progressively from the lean-
NL to the obese-NL to the obese-NA-
FLD groups (Table 1).
Plasma glucose, insulin, and C-peptide responses to glucose inges-
tion. Both plasma glucose concentrations and plasma glucose AUC 
after glucose ingestion were greater in the obese-NAFLD group 
than in the obese-NL and lean-NL groups, which were not signifi-
cantly different from each other (Figure 1, A and B). Plasma insu-
lin and C-peptide concentrations and AUC after glucose ingestion 
increased progressively from the lean-NL to the obese-NL to the 
obese-NAFLD groups (Figure 1, C–F). The plasma insulin concen-
tration AUC in the obese-NAFLD group was 2-fold greater than 
that in the obese-NL group and 3.5 times greater than in the lean-
NL group, whereas the plasma C-peptide concentration AUC was 
only 50% greater in the obese-NAFLD group than in the obese-NL 
group and 2-fold greater than in the lean-NL group.
Insulin kinetics. The kinetics model accurately described the 
insulin data from both the OGTT and HECP (average normal-
ized root mean square error: 6.3% ± 3.5%) (Supplemental Figure 
1; supplemental material available online with this article; https://
doi.org/10.1172/JCI136756DS1). The amount of insulin delivered 
to the liver comprises both insulin secreted by β cells and insulin 
that passes through the liver into the systemic circulation and is 
recycled back to the liver. Both the insulin secretion rate (ISR) 
and the rate of insulin recycled back to the liver during the 3-hour 
OGTT increased progressively from the lean-NL to the obese-NL 
to the obese-NAFLD groups (Figure 2A). Fractional hepatic insulin 
extraction (i.e., the fraction of insulin delivered to the liver that is 
removed by the liver) decreased progressively from the lean-NL to 
the obese-NL to the obese-NAFLD groups and was significantly 
lower in the obese-NAFLD group than in the obese-NL and lean-
NL groups (Figure 2B). However, the rate of total hepatic insulin 
extraction (i.e., the molar amount of insulin removed from plasma 
by the liver per minute) progressively increased from the lean-NL 
to the obese-NL to the obese-NAFLD groups and was greater in 
both the obese-NAFLD and obese-NL groups than in the lean-NL 
group, with no difference observed between the obese-NAFLD and 
obese-NL groups (Figure 2C). Although the fractional extraction 
insulin secretion was either increased or the same and insulin clear-
ance was either decreased or the same in individuals with NAFLD 
compared with those with normal IHTG content (15–18). The reason 
for the differences between studies could be related to differences in 
characteristics of the study subjects and the methods used to assess 
IHTG content and insulin metabolism.
The purpose of the present study was to provide a comprehen-
sive evaluation of the complex interrelationship among obesity, 
insulin resistance, hepatic steatosis, and insulin kinetics. A hyperin-
sulinemic-euglycemic clamp procedure (HECP), in conjunction with 
stable isotopically labeled glucose tracer infusion, and a 3-hour oral 
glucose tolerance test (OGTT) were used to evaluate insulin sensi-
tivity and insulin kinetics in 3 cohorts of individuals who differed in 
adiposity, insulin sensitivity, and IHTG content: (a) lean with normal 
IHTG content and normal fasting glucose and oral glucose tolerance 
(lean-NL), (b) obese with normal IHTG content and normal fasting 
glucose and oral glucose tolerance (obese-NL), and (c) obese with 
high IHTG content and evidence of abnormal glucose metabolism 
(impaired fasting glucose or oral glucose tolerance) (obese-NAFLD). 
We used a recently developed modeling approach (15, 19) in con-
junction with C-peptide deconvolution to assess different aspects of 
insulin kinetics in response to glucose ingestion, including the insu-
lin secretion rate and hepatic, extrahepatic, and whole-body insulin 
plasma clearance and tissue extraction rates. A better understand-
ing of the interrelationships among adiposity, IHTG content, insu-
lin sensitivity, and insulin kinetics can provide new insights into the 
mechanisms that regulate glucose homeostasis in individuals with 
obesity and those with obesity and NAFLD.
Results
Body composition and metabolic characteristics. The obese-NL and 
obese-NAFLD groups were matched with regard to BMI and body fat 
percentage, but IHTG content was 9-fold greater in the obese-NA-
FLD group than in the obese-NL group, with no difference in IHTG 
content between the lean-NL and obese-NL groups (Table 1). Fasting 
Table 1. Body composition and metabolic characteristics of the study subjects
Lean-NL (n = 14) Obese-NL (n = 24) Obese-NAFLD (n = 22)
Body weight, kg 65 ± 2 106 ± 4A 116 ± 4A
BMI, kg/m2 23 ± 1 38 ± 1A 40 ± 1A
FFM, kg 46 ± 2 55 ± 2A 59 ± 2A
Body fat, % 28 ± 2 47 ± 1A 48 ± 1A
IHTG content, % 1.6 ± 0.1 2.4 ± 0.2 21.0 ± 1.4A,B
HbA1c, % 5.0 ± 0.1 5.1 ± 0.1 5.7 ± 0.1A,B
Fasting glucose, mmol/L 4.7 ± 0.1 4.9 ± 0.1 5.6 ± 0.1A,B
Fasting insulin, pmol/L 36 ± 3 84 ± 7A 196 ± 23A,B
Fasting C-peptide, pmol/L 487 ± 34 826 ± 34A 1,491 ± 94A,B
OGTT 2-hour glucose, mmol/L 5.3 ± 0.3 6.0 ± 0.2 9.4 ± 0.3A,B
HISI, 100/(μmol/kg FFM/min × μU/mL) 1.13 ± 0.12 0.53 ± 0.04A 0.30 ± 0.03A,B
Glucose Rd/insulin, (nmol/kg FFM/min)/(pmol/L) 89 ± 6 56 ± 5A 30 ± 2A,B
Values represent the mean ± SEM. HISI, hepatic insulin sensitivity index. A 1-way ANOVA with post hoc 
testing where appropriate was used to identify significant mean differences among groups. AP < 0.05, value 
significantly different from the corresponding value in the lean-NL group; BP < 0.05, value significantly 
different from the corresponding value in the obese-NL group.
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observed in the obese-NL group, with consid-
erable variability in the rate of hepatic insulin 
extraction at any given rate of insulin delivery 
(Figure 2G). In contrast, the total extrahepatic 
insulin extraction rate increased linearly with 
increasing rates of insulin delivery into the sys-
temic circulation (i.e., total posthepatic insulin 
appearance in plasma) (Figure 2H).
Interrelationships among insulin sensitivity, 
plasma insulin concentration, IHTG content, and 
insulin kinetics. The whole-body insulin clear-
ance rate (i.e., volume of plasma cleared of insu-
lin per minute) during the OGTT was positively 
correlated with insulin sensitivity (assessed as 
the glucose rate of disposal relative to the plas-
ma insulin concentration [glucose Rd/I] during 
the HECP) (Figure 3A), whereas the whole-body 
insulin extraction rate (i.e., the molar amount of 
insulin removed per minute) was negatively correlated with mus-
cle insulin sensitivity (Figure 3B). The rate of whole-body insulin 
clearance was negatively correlated with the plasma insulin AUC 
during the OGTT (Figure 3C), whereas the whole-body insulin 
extraction rate was positively correlated with the plasma insulin 
AUC and was best described by a saturable, Michaelis-Menten 
relationship (ref. 20 and Figure 3D), presumably driven by the sat-
urability of hepatic insulin extraction. We observed no significant 
correlation between either the fractional hepatic insulin extraction 
rate or the total hepatic insulin extraction rate and IHTG content 
in the obese-NAFLD group (Supplemental Figure 2).
Indices of β cell function. The ISR during the OGTT was inversely 
correlated with muscle insulin sensitivity, and the ISR increased as 
muscle insulin sensitivity decreased in a curvilinear fashion (Figure 
4A). The β cell function index (i.e., the incremental ISR in relation 
to muscle insulin sensitivity), which provides a measure of insulin 
secretion by β cells in relation to insulin sensitivity, decreased pro-
gressively from the lean-NL to the obese-NL to the obese-NAFLD 
groups and was significantly lower in the obese- NAFLD group 
than in the lean-NL and obese-NL groups (Figure 4B). Therefore, 
the high ISR in the obese-NL group adequately compensated for 
the decrease in insulin sensitivity needed to maintain normal oral 
glucose tolerance. However, even the very high ISR in the obese- 
of insulin by extrahepatic tissues (i.e., the fraction of insulin deliv-
ered to extrahepatic tissues that is removed) was not different in 
the lean-NL (34% ± 2%), obese-NL (28% ± 3%), or obese-NAFLD 
(30% ± 2%) (P = 0.60) group, the rate of total extrahepatic insulin 
extraction (i.e., the molar amount of insulin removed by extrahe-
patic tissues per minute) progressively increased from the lean-NL 
to the obese-NL to the obese-NAFLD groups and was more than 
double the rate in the obese-NAFLD group than in the obese-
NL group (Figure 2D). The rate of total (whole-body) insulin 
extraction increased progressively from the lean-NL to the obese-
NL to the obese-NAFLD groups because of increases in both total 
hepatic and extrahepatic insulin extraction rates (Figure 2E). The 
liver accounted for approximately 70% of whole-body insulin 
extraction in the lean-NL and obese-NL groups, but only approxi-
mately 50% in the obese-NAFLD group; conversely, extrahepatic 
insulin extraction increased from approximately 30% of whole-
body insulin extraction in the lean-NL and obese-NL groups to 
approximately 50% in the obese-NAFLD group (Figure 2F). The 
relationship between the rate of insulin delivered to the liver (i.e., 
ISR and posthepatic insulin that is not removed by extrahepat-
ic tissues and is recycled back to the liver) and the rate of total 
hepatic insulin extraction demonstrated a saturable process that 
began to plateau with the increase in hepatic insulin delivery rates 
Figure 1. Plasma glucose, insulin, and C-peptide 
responses to glucose ingestion. Plasma glucose, 
insulin, and C-peptide concentrations before and over 
a 3-hour period after ingesting a 75-g glucose drink 
(A, C, and E), and plasma glucose, insulin, and C-pep-
tide 3-hour concentration AUC values (B, D, and F) in 
the lean-normal (NL), obese-NL, and obese-NAFLD 
groups. White, gray, and black circles in A, C, and E 
represent the lean-NL (n = 14), obese-NL (n = 24), and 
obese-NAFLD (n = 22) groups, respectively. Values in 
B, D, and F represent the mean ± SEM. P values were 
determined by 1-way ANOVA with post hoc testing to 
identify significant mean differences between groups 
when appropriate. *P < 0.05, value significantly 
different from the lean-NL value; †P < 0.05, value 
significantly different from the obese-NL value.
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of hepatic and muscle insulin sensitivity mea-
sured during the HECP, these groups repre-
sented a progressive deterioration in insulin 
sensitivity from the lean-NL to the obese-
NL to the obese-NAFLD groups. We used a 
recently developed modeling approach (15, 
19) and C-peptide deconvolution to provide 
a comprehensive analysis of insulin kinet-
ics in response to glucose ingestion, includ-
ing insulin secretion by β cells and hepatic, 
extrahepatic, and whole-body insulin plas-
ma clearance and tissue extraction rates. 
The major findings from our study are: (a) 
the ISR in response to glucose ingestion pro-
gressively increased from the lean-NL to the 
obese-NL to the obese-NAFLD groups, but β 
cell function, assessed as the increase in ISR in relation to insulin 
sensitivity, was lower in the obese-NAFLD group than in the lean-
NL and obese-NL groups; (b) hepatic steatosis does not impair the 
rate of hepatic insulin extraction (molar amount of insulin removed 
from plasma per unit of time), and total hepatic insulin extraction 
rates were greater in the obese-NL and obese-NAFLD groups 
than in the lean-NL group, but were not different between the 
obese-NAFLD and obese-NL groups; (c) the rate of total extrahe-
patic insulin extraction progressively increased from the lean-NL 
to the obese-NL to the obese-NAFLD groups; (d) the total hepat-
ic insulin extraction rate plateaued when hepatic insulin delivery 
NAFLD group was not adequate to compensate for the further 
decrease in insulin sensitivity in the obese- NAFLD group, resulting 
in abnormal glucose tolerance (Figure 1A).
Discussion
We conducted an OGTT and a HECP in 3 carefully characterized 
cohorts of participants who were either lean with normal glucose 
tolerance and normal IHTG content, obese with normal glucose 
tolerance and normal IHTG content, or obese with prediabetes and 
NAFLD to help dissect the effects of adiposity, insulin resistance, 
and hepatic steatosis on insulin kinetics. Based on the assessment 
Figure 2. Insulin kinetics after glucose inges-
tion. Rate of total insulin delivered to the liver, 
comprising the rate of insulin secreted from β 
cells (white bars) and the rate of insulin recycled 
from the systemic circulation back to the liver 
(gray bars) (A), fractional hepatic insulin extraction 
(B), rate of total hepatic insulin extraction (C), 
rate of total extrahepatic insulin extraction (D), 
absolute contribution of hepatic (white bars) and 
extrahepatic (gray bars) insulin extraction to the 
total rate of whole-body insulin extraction (E), and 
relative contribution of hepatic (white bars) and 
extrahepatic (gray bars) extraction to the total rate 
of whole-body insulin extraction (F) in the lean-NL 
(n = 14), obese-NL (n = 23), and obese-NAFLD (n 
= 21) groups. Values represent the mean ± SEM 
and indicate the averages for 3 hours after glucose 
ingestion. A 1-way ANCOVA with race and sex as 
covariates and post hoc testing where appropriate 
were used to identify significant mean differences 
between groups. *P < 0.05, value significantly 
different from the lean-NL value; † P < 0.05, value 
significantly different from the obese-NL value. 
Relationship between insulin delivery to the liver 
and the rate of total hepatic insulin extraction 
(G) and relationship between the insulin delivery 
rate into the systemic circulation and the rate of 
total extrahepatic insulin extraction (H) in lean-NL 
(white circles; n = 14), obese-NL (gray circles; n = 
23), and obese-NAFLD (black circles; n = 21) partic-
ipants. Logarithmic and linear regression analyses 
were performed to determine the line of best fit to 
the data in G and H, respectively.
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of insulin to the liver (prehepatic insulin) from 
lean-NL to obese-NL to obese-NAFLD groups. 
The liver’s ability to increase the rate of insulin 
extraction when insulin delivery to the liver was 
increased, as in the obese-NL and obese-NA-
FLD groups, was limited, presumably because 
of a saturable hepatic insulin transport system 
(21–23). Therefore, an increase in the delivery of insulin to the 
liver was associated with a decrease in fractional hepatic insulin 
extraction, and more insulin passed through the liver into the sys-
temic circulation. Most of the insulin that entered the systemic 
circulation (posthepatic insulin) was recycled back to the liver, 
but a progressively increasing amount of insulin was removed by 
extrahepatic tissues (primarily the kidneys and skeletal muscle) 
(6, 8) in the lean-NL, obese-NL, and obese-NAFLD groups. In all 
groups, more than 99% of insulin secreted by β cells was removed 
by hepatic and extrahepatic tissues during the 180-minute OGTT. 
However, small differences between the rate of insulin secretion 
and removal among the 3 groups resulted in marked differences 
in plasma insulin concentration at the 180-minute time point (60 
± 22, 158 ± 38, and 532 ± 80 pmol/L in the lean-NL, obese-NL, 
and obese-NALFD groups, respectively) (Figure 1C). These results 
demonstrate that the major factor responsible for hyperinsulin-
emia in individuals with obesity who have insulin resistance and 
NAFLD is β cell hypersecretion in conjunction with a saturable 
insulin extraction process in the liver.
Although there was a large range in IHTG content in the 
obese-NAFLD group, we found no correlation between either 
fractional hepatic insulin extraction or the rate of total hepatic 
insulin extraction and the severity of steatosis. In addition, the 
total hepatic insulin extraction rate was not significantly differ-
ent between the obese-NAFLD and obese-NL groups. These 
results challenge the notion that NAFLD per se impairs hepatic 
insulin extraction. However, we also found considerable vari-
ability in the hepatic insulin extraction rate at any given rate of 
insulin delivery to the liver in the obese-NL and obese-NAFLD 
groups. The reasons for the heterogeneity in the rates of total 
hepatic insulin extraction are not clear but could be related to 
individual subject variability in some of the assumed values the 
kinetic model uses, such as hepatic blood flow and C-peptide 
(from newly secreted and recycled insulin) was high, whereas the 
total extrahepatic insulin extraction rate increased linearly with 
increasing delivery of insulin into the systemic circulation; and (e) 
the whole-body insulin clearance rate (volume of plasma cleared of 
insulin) was positively correlated, whereas the whole-body insulin 
extraction rate (the molar amount of insulin removed by all tissues) 
was negatively correlated with muscle insulin sensitivity. Our data 
demonstrate that the greater increase in plasma insulin concentra-
tions in response to an oral glucose challenge in the obese-NL and 
obese-NAFLD groups compared with that observed in the lean-NL 
group is due to an increase in insulin secretion, not a reduction in 
total insulin extraction by the liver or extrahepatic tissues. How-
ever, the liver’s capacity to remove insulin is a saturable process 
that reaches maximum capacity when hepatic insulin delivery 
is high, which occurred after glucose ingestion in our obese-NL 
and obese-NAFLD subjects. In contrast, extrahepatic insulin 
extraction after glucose ingestion increased linearly with increases 
in insulin delivery into the systemic circulation. Nonetheless, the 
marked increases in hepatic and extrahepatic insulin delivery and 
extraction in the obese-NAFLD group were not adequate to com-
pensate for the decrease in insulin sensitivity, resulting in impaired 
glucose homeostasis.
Systemic plasma insulin concentration is determined by the 
rate of insulin secretion by β cells and the rate of insulin removal 
by the liver and extrahepatic tissues. The results from our study 
provide an integrated assessment of insulin kinetics in response 
to an oral glucose challenge, including rates of insulin secretion, 
hepatic and extrahepatic insulin extraction, and recycling of pos-
thepatic insulin back to the liver in distinct cohorts of individuals 
who differed in adiposity, IHTG content, and hepatic and mus-
cle insulin sensitivity (Figure 5). The data demonstrate that both 
insulin secreted by the pancreas and insulin recycled from the 
systemic circulation progressively increased the total delivery 
Figure 3. Relationships among insulin sensitivity 
and insulin concentration after glucose ingestion and 
whole-body insulin clearance and extraction rates. 
Relationships among whole-body insulin clearance 
and extraction rates assessed for 3 hours after inges-
tion of a 75-g glucose drink and muscle insulin sensi-
tivity, calculated as the glucose Rd (in nmol/kg FFM/
min) divided by the plasma insulin (I) concentration 
(in pmol/L) during a HECP (A and B), and the plasma 
insulin concentration AUC (C and D). White, gray, and 
black circles represent participants in the lean-NL (n 
= 14), obese-NL (n = 24 in A and C and n = 23 in B and 
D), and obese-NAFLD (n = 22 in A and C and n = 21 in 
B and D) groups, respectively. Logarithmic regression 
analysis was used to determine the lines of best fit to 
the data in A–C, with Michaelis-Menten kinetics used 
to describe the line of best fit in D.
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kinetics, differences in the expression of insulin receptors, and 
differences in the content of intrahepatic proteins involved in 
insulin degradation, namely hepatic carcinoembryonic anti-
gen–related cell adhesion molecule 1 (CEACAM1) and insu-
lin-degrading enzyme (IDE) (24).
In individuals with normal glucose tolerance, there is a hyper-
bolic relationship between insulin sensitivity and the increase in 
plasma insulin concentration in response to an oral or intravenous 
glucose challenge; the product of these 2 variables is known as the 
disposition index (DI) (25–27). Accordingly, DI values are main-
tained when a decrease or increase in insulin sensitivity is com-
pensated by a corresponding increase or decrease, respectively, in 
the plasma insulin response to a glucose load (28–30). However, 
the prevailing plasma insulin concentration is a function of both 
the rate of insulin secretion and the rate of insulin removal. There-
fore, the DI concept implies that β cells and the liver are somehow 
able to sense changes in whole-body insulin sensitivity and adjust 
the rate of insulin secretion and removal as needed to prevent 
hypoglycemia, while increasing circulating insulin to compensate 
for insulin resistance. The data from our study suggest that insulin 
secretion drives this process, whereas hepatic insulin extraction 
is likely a passive function of insulin delivery that becomes sat-
urated at high insulin delivery rates. Despite the very high ISR 
and plasma insulin concentrations after glucose ingestion in the 
obese-NAFLD group, postprandial plasma glucose concentrations 
were much higher in the obese-NAFLD group than in the obese-
NL and lean-NL groups. Therefore, the increased β cell response 
and increase in plasma insulin concentrations in the obese-NA-
FLD group were unable to compensate for the increase in insulin 
resistance, which is consistent with the observed lower β cell func-
tion index (i.e., incremental insulin secretion in relation to insulin 
sensitivity) in the obese-NAFLD group than in the lean-NL and 
obese-NL groups.
Our study was unable to determine whether the increased 
ISRs in the obese-NL and obese-NAFLD groups were a cause or a 
consequence of insulin resistance, or possibly both. The increased 
ISRs could be due to a proposed β cell compensatory response to 
insulin resistance (31), which is consistent with the inverse correla-
tion between the ISR and whole-body insulin sensitivity observed 
among subjects in our entire cohort. However, the mechanism 
responsible for the ability of the β cell to “sense” insulin resistance 
in other tissues has not been identified. Increased insulin secre-
tion can also be caused by intrinsic β cell hyperreactivity to sub-
strate, hormonal and neural stimuli, and even environmental pol-
lutants (32, 33). In addition, the normal feedback suppression of 
insulin secretion by circulating insulin is blunted in obese individ-
uals (34). Accordingly, hyperinsulinemia in individuals with obesi-
ty could lead to a “vicious insulin cycle,” in which increased insu-
lin secretion causes insulin resistance, which in turn stimulates 
increased insulin secretion. The high rate of insulin secretion and 
plasma insulin concentrations can have adverse long-term clini-
cal consequences, because a high ISR is a risk factor for develop-
ing type 2 diabetes (29, 32). These findings suggest that the most 
effective approach for preventing prediabetes and type 2 diabetes 
in obese individuals should include interventions that decrease 
insulin secretion and plasma concentration (35, 36).
Several limitations of our study should be considered. First, 
differences in insulin secretion and clearance rates have been 
reported among different racial/ethnic groups (37–39), so the 
results from our study, which primarily included White (65%) 
and African American (27%) participants, might not apply to oth-
er racial/ethnic populations. In an effort to reduce the potential 
confounding effect of race, we included race as a covariate in our 
statistical analyses. In addition, we performed additional anal-
yses that evaluated the data from the White and African Ameri-
can participants separately. All significant differences between 
lean-NL, obese-NL, and obese-NAFLD groups and significant 
correlations between outcome measures were maintained when 
evaluating White participants only. The same pattern of differenc-
es in outcomes between groups and the correlations between out-
comes were maintained for the African American participants, but 
some of these assessments did not achieve statistical significance 
because of inadequate sample size in this subgroup. Second, the 
model used to assess insulin kinetics includes estimated values 
for C-peptide kinetic parameters and hepatic blood flow that are 
based on standard estimates that do not fully account for inter-
individual variability and are assumed to be the same during the 
Figure 4. Indices of β cell function. (A) Relationship between muscle insu-
lin sensitivity, calculated as the glucose Rd (in nmol/kg FFM/min) divided 
by the plasma insulin (I) concentration (in pmol/L) during a HECP, and the 
mean insulin secretion rate, assessed for 3 hours after ingestion of a 75-g 
glucose drink in lean-NL (white circles; n = 14), obese-NL (gray circles; n 
= 24), and obese-NAFLD (black circles; n = 22) participants. Logarithmic 
regression analysis was used to determine the line of best fit to the data. 
(B) β Cell function index, calculated as the product of the incremental 
insulin secretion rate (in nmol × min) for 3 hours after glucose ingestion 
(ΔISR0–180) and muscle insulin sensitivity. Values represent the mean ± 
SEM. A 1-way ANCOVA with race and sex as covariates and post hoc test-
ing where appropriate were used to identify significant mean differences 
between groups. *P <0.05, value significantly different from the lean-NL 
value; †P <0.05, value significantly different from the obese-NL value.
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OGTT and the HECP. Third, our study is a cross-sectional analysis 
of weight-stable participants, so we cannot exclude the possibility 
that changes in insulin kinetics occur over time or in response to 
changes in diet or body weight.
In summary, the large increase in plasma insulin concentra-
tions in response to an oral glucose challenge that is commonly 
observed in individuals with obesity and further exacerbated in 
individuals with obesity who have NAFLD and greater insulin 
resistance was driven by increased insulin secretion, without 
an intrinsic defect in hepatic or extrahepatic insulin extraction. 
Therefore, the progressive decrease in whole-body insulin clear-
ance rates (volume of plasma cleared of insulin per unit of time) 
from lean-NL to obese-NL to obese-NAFLD was probably a conse-
quence, rather than a cause, of hyperinsulinemia. The rate of insu-
lin extraction by the liver, but not by extrahepatic tissues, became 
saturable when the postprandial delivery of insulin to the liver was 
high. In individuals with severe insulin resistance, the increased 
delivery of insulin to the liver and extrahepatic tissues was unable 
to compensate for the decrease in insulin sensitivity, resulting in 
impaired glucose homeostasis.
Methods
Subjects. A total of 60 men and women participated in this study 
(see Supplemental Figure 3 for the flow chart of study subjects). 
Subjects were recruited using the Volunteers for Health database 
at Washington University School of Medicine and by local postings 
between April 2016 and November 2018. All procedures for this 
study were conducted in the Clinical Translational Research Unit 
(CTRU) and Center for Clinical Imaging Research (CCIR) at Wash-
ington University School of Medicine. Potential subjects completed 
an initial evaluation that included a medical history and physical 
examination, standard blood tests, a 3-hour OGTT and an assess-
ment of body composition including IHTG content. Subjects were 
enrolled if they met the criteria for inclusion in 1 of 3 groups: (a) 
lean-NL individuals, defined as having a BMI of 18.5 to 24.9 kg/m2 
and normal fasting plasma glucose (<100 mg/dL), oral glucose tol-
erance (2-hour glucose <140 mg/dL), and IHTG content (≤5%) (n = 
14; age: 36 ± 2 yr; sex: 7 men and 7 women; race: 9 Whites, 1 African 
American, and 4 Asians); (b) obese-NL individuals, defined as hav-
ing a BMI of 30.0 to 49.9 kg/m2 and normal fasting plasma glucose, 
oral glucose tolerance, and IHTG content (n = 24; age: 39 ± 2 yr; 
Figure 5. Integrated summary of insulin kinetics after glucose ingestion. Values represent the mean rates (in pmol/min) for β cell insulin secretion, tis-
sue insulin extraction, and insulin accumulation in the systemic circulation, assessed for 3 hours after ingestion of a 75-g glucose drink. Insulin secretion 
by the pancreas into the portal circulation increased progressively from the lean-NL to the obese-NL to the obese-NAFLD groups. In addition, a large 
portion of insulin that entered the portal circulation was not immediately removed by the liver and extrahepatic tissues and was recycled back to the liver 
via the portal vein and hepatic artery, so the total amount of insulin delivered to the liver (newly secreted and recycled insulin) also increased progressively 
from the lean-NL to the obese-NL to the obese-NAFLD groups. Although the fractional hepatic extraction of delivered insulin progressively decreased, the 
rate of total hepatic insulin extraction progressively increased from the lean-NL to the obese-NL to the obese-NAFLD groups. However, the rate of hepatic 
insulin extraction plateaued when the delivery of insulin to the liver was high, as in the obese-NL and obese-NAFLD groups, because of a saturable hepatic 
insulin transport system. Most of the insulin that passes through the liver and enters the systemic circulation is recycled back to the liver, and a progres-
sively increasing amount of insulin was removed by extrahepatic tissues (primarily the kidneys and skeletal muscle) in subjects in the lean-NL, obese-NL, 
and obese-NAFLD groups. A small portion of insulin that entered the systemic circulation (posthepatic insulin) was not removed by 180 minutes after 
glucose ingestion and was responsible for the increase in plasma insulin concentration above baseline at the 180-minute time point.
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glucose Rd during insulin infusion was assumed to be equal to the sum 
of the endogenous glucose rate of appearance into the bloodstream 
and the rate of infused glucose during the last 20 minutes of the HECP 
(1). An index of muscle insulin sensitivity was calculated as the glucose 
Rd expressed per kilogram of FFM divided by the plasma insulin con-
centration (glucose Rd/I) during the final 20 minutes of the HECP. 
Insulin secretion rates were calculated using C-peptide deconvolution 
(43). Insulin secretion in relationship to insulin sensitivity was used to 
provide an index of β cell function and calculated as the product of the 
incremental AUC in the ISR above time 0 from 0 to 180 minutes of the 
OGTT, and insulin sensitivity was assessed during the HECP (ΔISR0-180 
× glucose Rd/I).
The whole-body insulin clearance rate (i.e., volume of plasma 
cleared of insulin per minute) was calculated using a 1-compartment 
model for plasma insulin: (AUC ISR/AUC I) – V × (I180 – I0)/AUC I, 
where V is the distribution volume for insulin estimated as 141 mL/
kg (19), and I0 and I180 are the plasma insulin concentrations at time 0 
(baseline) and 180 minutes, respectively, during the OGTT. A recently 
developed mathematical modeling approach that involves the use of 
plasma insulin concentration and ISR data from both the OGTT and 
HECP (15, 19) was used to provide a comprehensive assessment of 
the kinetics of hepatic and extrahepatic insulin removal from plasma 
during the OGTT. In this model, hepatic insulin clearance for each 
subject was modeled using either a linear or saturable model, and the 
model that provided the better fit was used for that subject. In addi-
tion, extrahepatic insulin clearance was assumed to be linear; this 
assumption was confirmed by testing a saturable model for extrahe-
patic insulin clearance, and finding a linear model provided the best 
fit of the data for all subjects. The following measurements of insu-
lin kinetics were determined: (a) fractional hepatic insulin extraction 
(i.e., the fraction of insulin delivered to the liver that is removed by 
the liver); (b) total hepatic insulin extraction rate (i.e., molar amount 
of insulin removed from plasma by the liver per minute); (c) rate of 
insulin recycled from the systemic circulation back to the liver (i.e., 
insulin that passes through the liver into the systemic circulation that 
is not removed by extrahepatic tissues and is recycled back to the liv-
er); (d) rate of extrahepatic insulin extraction (i.e., molar amount of 
insulin removed from plasma by extrahepatic tissues per unit of time); 
and (e) whole-body insulin extraction rate (i.e., sum of the hepatic and 
extrahepatic insulin extraction rates).
Statistics. A 1-way ANOVA was used to compare characteristics 
of subjects in the lean-NL, obese-NL, and obese-NAFLD groups. 
Between-group differences in the insulin secretion rate, clearance 
rate, total extraction rate, and fractional extraction were assessed 
using ANCOVA with race and sex as covariates. Where appropriate, 
post hoc analyses were used to locate significant mean differences. 
Modeled and measured plasma insulin concentration profiles were 
compared using the normalized root mean square error, as previously 
described (15, 19). The significance of the relationships among out-
come measures were evaluated using either linear or nonlinear regres-
sion. Relationships that involved IHTG content were analyzed sepa-
rately for subjects with normal IHTG content (lean-NL and obese-NL 
groups) and high IHTG content (obese-NAFLD group), because there 
was no continuum in IHTG content according to the study’s design. 
The relationship between the whole-body insulin extraction rate and 
the plasma insulin concentration AUC during the OGTT was assessed 
using Michaelis-Menten kinetics to determine whether the rate of 
sex: 3 men, 21 women; race: 13 Whites and 11 African Americans); 
and (c) obese-NAFLD individuals, defined as having a BMI of 30.0 
to 49.9 kg/m2, impaired fasting glucose or oral glucose tolerance, 
and high IHTG content (≥10%) (n = 22; age: 42 ± 2 yr; sex: 6 men 
and 16 women; race: 17 Whites, 4 African Americans, and 1 Pacific 
Islander). None of the subjects had evidence of diabetes, serious ill-
nesses other than NAFLD, was taking medications that could inter-
fere with insulin action or secretion, consumed excessive amounts 
of alcohol (>14 drinks/week for women and >21 drinks/week for 
men), or smoked tobacco products.
Body composition analyses. Total body fat and fat-free mass (FFM) 
were determined by using dual-energy x-ray absorptiometry (Lunar 
iDXA, GE Healthcare), and IHTG content was determined by MRI 
(3.0-T superconducting magnet; Siemens) (5).
OGTT. Subjects were admitted to the CTRU at Washington Uni-
versity School of Medicine at 0700 hours after subjects fasted for 
approximately 11 hours overnight at home. An intravenous catheter 
was inserted into an antecubital or hand vein for serial blood sam-
pling. Plasma glucose, insulin, and C-peptide concentrations were 
determined 15, 10, and 5 minutes before and 10, 20, 30, 60, 90, 120, 
150, and 180 minutes after consuming a 75-g glucose beverage. The 
average of the 3 baseline samples (i.e., –15, –10, and –5 minutes before 
consuming the 75-g glucose beverage) was used as the t = 0 glucose, 
insulin, and plasma C-peptide concentrations.
HECP. Subjects were admitted to the CTRU at 1800 hours for 
approximately 48 hours. Participants were given standard meals con-
taining one-third of their estimated energy requirements (40) upon 
admission (day 0) and at 0700 hours, 1300 hours, and 1900 hours on 
day 1. The HECP was performed on day 2, after subjects fasted over-
night. At 0700 hours, a primed (8.0 μmol/kg), continuous (0.08 μmol/
kg/min) infusion of [U-13C]glucose (Cambridge Isotope Laboratories 
Inc.) was started. After the infusion of glucose tracer for 3.5 hours (bas-
al period), insulin was infused at a rate of 50 mU/m2/min (initiated 
with a 2-step priming dose of 200 mU/m2/min for 5 minutes followed 
by 100 mU/m2/min for 5 minutes), and euglycemia (~100 mg/dL) was 
maintained by variable-rate infusion of a 20% dextrose solution that 
was enriched to approximately 1% with [U-13C]glucose. The infusion 
of [U-13C]glucose was stopped during insulin infusion because of the 
expected decrease in hepatic glucose production. Blood samples were 
obtained before beginning the glucose tracer infusion and every 6 to 
7 minutes during the last 20 minutes of the basal and insulin infusion 
stages to determine glucose, C-peptide, and insulin concentrations 
and glucose kinetics.
Sample analyses and calculations. Blood samples were collected in 
chilled tubes containing EDTA or heparin and placed in ice. Plasma 
was separated by centrifugation within 30 minutes of collection and 
then stored at –80°C until final analyses. The plasma glucose concen-
tration was determined using the glucose oxidase method (YSI Inc.), 
and plasma insulin and C-peptide concentrations were determined 
using electrochemiluminescence assays (Elecsys 2010, Roche Diag-
nostics). The plasma glucose tracer-to-tracee ratio was determined by 
gas-chromatography/mass-spectrometry as described previously (41).
Plasma glucose, insulin, and C-peptide concentration AUCs 
during the OGTT were calculated using the trapezoidal method (42). 
Hepatic insulin sensitivity was calculated as the reciprocal of the prod-
uct of the basal endogenous glucose production rate (in μmol/kg FFM/
min) and the basal plasma insulin concentration (in μU/mL) (1). Total 
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data and the accuracy of the data analysis. All authors critically 
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